Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells.

Luo Y, Meyer N, Jiao Q, Scheffel J, Zimmermann C, Metz M, Zenclussen A, Maurer M, Siebenhaar F.

Front Immunol. 2019 Oct 15;10:2399. doi: 10.3389/fimmu.2019.02399. eCollection 2019.

2.

Mast cells are critical for controlling the bacterial burden and the healing of infected wounds.

Zimmermann C, Troeltzsch D, Giménez-Rivera VA, Galli SJ, Metz M, Maurer M, Siebenhaar F.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20500-20504. doi: 10.1073/pnas.1908816116. Epub 2019 Sep 23.

PMID:
31548430
3.

Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab.

Buttgereit T, Bonnekoh H, Church MK, Bergmann KC, Siebenhaar F, Metz M.

J Dtsch Dermatol Ges. 2019 Sep 3. doi: 10.1111/ddg.13926. [Epub ahead of print] No abstract available.

PMID:
31479567
4.

Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the Anaphylaxis Registry (NORA).

Dölle-Bierke S, Siebenhaar F, Burmeister T, Worm M.

J Allergy Clin Immunol. 2019 Nov;144(5):1448-1450.e1. doi: 10.1016/j.jaci.2019.07.037. Epub 2019 Aug 12. No abstract available.

PMID:
31415784
5.

Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions.

Maurer M, Taube C, Schröder NWJ, Ebmeyer J, Siebenhaar F, Geldmacher A, Schubert N, Roers A.

J Allergy Clin Immunol. 2019 Oct;144(4S):S19-S30. doi: 10.1016/j.jaci.2019.07.017. Epub 2019 Jul 29.

PMID:
31369803
6.

The Henna pigment Lawsone activates the Aryl Hydrocarbon Receptor and impacts skin homeostasis.

Lozza L, Moura-Alves P, Domaszewska T, Lage Crespo C, Streata I, Kreuchwig A, Puyskens A, Bechtle M, Klemm M, Zedler U, Silviu Ungureanu B, Guhlich-Bornhof U, Koehler AB, Stäber M, Mollenkopf HJ, Hurwitz R, Furkert J, Krause G, Weiner J 3rd, Jacinto A, Mihai I, Leite-de-Moraes M, Siebenhaar F, Maurer M, Kaufmann SHE.

Sci Rep. 2019 Jul 26;9(1):10878. doi: 10.1038/s41598-019-47350-x.

7.

Diagnosis and treatment of chronic inducible urticaria.

Maurer M, Hawro T, Krause K, Magerl M, Metz M, Siebenhaar F, Terhorst-Molawi D, Weller K, Zuberbier T, Altrichter S.

Allergy. 2019 May 18. doi: 10.1111/all.13878. [Epub ahead of print] No abstract available.

PMID:
31102545
8.

Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, Nedoszytko B, Siebenhaar F, Sperr WR, Oude Elberink JNG, Butterfield JH, Alvarez-Twose I, Sotlar K, Reiter A, Kluin-Nelemans HC, Hermine O, Gotlib J, Broesby-Olsen S, Orfao A, Horny HP, Triggiani M, Arock M, Schwartz LB, Metcalfe DD.

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1125-1133.e1. doi: 10.1016/j.jaip.2019.01.006. Epub 2019 Feb 5. Review.

PMID:
30737190
9.

Chronische Urtikaria - Was bringt die neue Leitlinie?

Maurer M, Zuberbier T, Siebenhaar F, Krause K.

J Dtsch Dermatol Ges. 2018 May;16(5):585-595. doi: 10.1111/ddg.13531_g. No abstract available.

PMID:
29750471
10.

Chronic urticaria - What does the new guideline tell us?

Maurer M, Zuberbier T, Siebenhaar F, Krause K.

J Dtsch Dermatol Ges. 2018 May;16(5):584-593. doi: 10.1111/ddg.13531.

PMID:
29750467
11.

Development and validation of the mastocytosis activity score.

Siebenhaar F, Sander B, Ho LHT, Ellrich A, Maurer M, Weller K.

Allergy. 2018 Jul;73(7):1489-1496. doi: 10.1111/all.13425. Epub 2018 Mar 1.

PMID:
29405310
12.

Mast Cells as Drivers of Disease and Therapeutic Targets.

Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M.

Trends Immunol. 2018 Feb;39(2):151-162. doi: 10.1016/j.it.2017.10.005. Epub 2017 Nov 28. Review.

PMID:
29196147
13.

Development of tripe palms and soles in a patient with long pre-existing systemic mastocytosis and newly developed non-small cell lung cancer.

Bonnekoh H, Ohanyan T, Lenze D, Krause K, Maurer M, Zuberbier T, Siebenhaar F.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e151-e153. doi: 10.1111/jdv.14648. Epub 2017 Nov 7. No abstract available.

PMID:
29055165
14.

Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.

Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, Siebenhaar F, Møller MB, Kristensen TK, Bindslev-Jensen C; Mastocytosis Centre Odense University Hospital (MastOUH).

Allergy. 2018 Jan;73(1):230-238. doi: 10.1111/all.13237. Epub 2017 Jul 27.

PMID:
28662309
15.

Clinical Measures of Chronic Urticaria.

Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M.

Immunol Allergy Clin North Am. 2017 Feb;37(1):35-49. doi: 10.1016/j.iac.2016.08.005. Epub 2016 Nov 1. Review.

PMID:
27886909
16.

Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure.

Gimenez-Rivera VA, Siebenhaar F, Zimmermann C, Siiskonen H, Metz M, Maurer M.

J Immunol. 2016 Dec 1;197(11):4240-4246. Epub 2016 Nov 2.

17.

Histamine intolerance in patients with chronic spontaneous urticaria.

Siebenhaar F, Melde A, Magerl M, Zuberbier T, Church MK, Maurer M.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1774-1777. doi: 10.1111/jdv.13778. Epub 2016 Jun 22.

PMID:
27329741
18.

Controversies and challenges in the management of chronic urticaria.

Staubach P, Zuberbier T, Vestergaard C, Siebenhaar F, Toubi E, Sussman G.

J Eur Acad Dermatol Venereol. 2016 Jul;30 Suppl 5:16-24. doi: 10.1111/jdv.13696. Review.

PMID:
27286499
19.

Questions and answers in chronic urticaria: where do we stand and where do we go?

Maurer M, Church MK, Marsland AM, Sussman G, Siebenhaar F, Vestergaard C, Broom B.

J Eur Acad Dermatol Venereol. 2016 Jul;30 Suppl 5:7-15. doi: 10.1111/jdv.13695. Review.

PMID:
27286498
20.

Innovative approaches to avoid electric shaving-induced skin irritation.

Rietzler M, Maurer M, Siebenhaar F, Angelino S, Handt J, Burghardt R, Smetana H.

Int J Cosmet Sci. 2016 Jun;38 Suppl 1:10-6. doi: 10.1111/ics.12329. Review.

PMID:
27212466
21.

The male beard hair and facial skin - challenges for shaving.

Maurer M, Rietzler M, Burghardt R, Siebenhaar F.

Int J Cosmet Sci. 2016 Jun;38 Suppl 1:3-9. doi: 10.1111/ics.12328. Review.

PMID:
27212465
22.

Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.

Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, Wagner N, Martus P, Carter MC, Metcalfe DD, Church MK, Maurer M, Weller K.

Allergy. 2016 Jun;71(6):869-77. doi: 10.1111/all.12842. Epub 2016 Feb 15.

PMID:
26797792
23.

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.

Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hägglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P.

J Allergy Clin Immunol. 2016 Jan;137(1):35-45. doi: 10.1016/j.jaci.2015.08.034. Epub 2015 Oct 21. Review.

PMID:
26476479
24.

Murine and human mast cell progenitors.

Schmetzer O, Valentin P, Church MK, Maurer M, Siebenhaar F.

Eur J Pharmacol. 2016 May 5;778:2-10. doi: 10.1016/j.ejphar.2015.07.016. Epub 2015 Jul 8. Review.

PMID:
26164789
25.

An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria.

Magerl M, Abajian M, Krause K, Altrichter S, Siebenhaar F, Church MK.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2043-5. doi: 10.1111/jdv.12739. Epub 2014 Sep 30.

PMID:
25266078
26.

The search for mast cell and basophil models--are we getting closer to pathophysiological relevance?

Siebenhaar F, Falcone FH, Tiligada E, Hammel I, Maurer M, Sagi-Eisenberg R, Levi-Schaffer F.

Allergy. 2015 Jan;70(1):1-5. doi: 10.1111/all.12517. No abstract available.

PMID:
25155287
27.

Mast cell-mediated reactions in vivo.

Giménez-Rivera VA, Metz M, Siebenhaar F.

Methods Mol Biol. 2014;1192:239-47. doi: 10.1007/978-1-4939-1173-8_18.

PMID:
25149497
28.

Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood.

Broesby-Olsen S, Oropeza AR, Bindslev-Jensen C, Vestergaard H, Møller MB, Siebenhaar F, Kristensen T, Mortz CG; Mastocytosis Centre Odense University Hospital (MastOUH); Odense Research Centre for Anaphylaxis.

J Allergy Clin Immunol. 2015 Jan;135(1):262-4. doi: 10.1016/j.jaci.2014.06.031. Epub 2014 Aug 1. No abstract available.

PMID:
25091436
29.

A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs).

Schmetzer O, Valentin P, Smorodchenko A, Domenis R, Gri G, Siebenhaar F, Metz M, Maurer M.

J Immunol Methods. 2014 Nov;413:62-8. doi: 10.1016/j.jim.2014.07.003. Epub 2014 Jul 17.

PMID:
25038510
30.

Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?

Woidacki K, Zenclussen AC, Siebenhaar F.

Front Immunol. 2014 May 19;5:231. doi: 10.3389/fimmu.2014.00231. eCollection 2014. Review.

31.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis.

Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M; European Competence Network on Mastocytosis.

Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436. Epub 2014 May 19.

PMID:
24836395
32.

Treatment strategies in mastocytosis.

Siebenhaar F, Akin C, Bindslev-Jensen C, Maurer M, Broesby-Olsen S.

Immunol Allergy Clin North Am. 2014 May;34(2):433-47. doi: 10.1016/j.iac.2014.01.012. Epub 2014 Mar 13. Review.

PMID:
24745685
33.

Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model.

Siebenhaar F, Metz M, Maurer M.

Exp Dermatol. 2014 Mar;23(3):159-64. doi: 10.1111/exd.12328.

PMID:
24444017
34.

Cardioprotective C-kit⁺ bone marrow cells attenuate apoptosis after acute myocardial infarction in mice - in-vivo assessment with fluorescence molecular imaging.

Ale A, Siebenhaar F, Kosanke K, Aichler M, Radrich K, Heydrich S, Schiemann M, Bielicki I, Noel PB, Braren R, Maurer M, Walch AK, Rummeny EJ, Ntziachristos V, Wildgruber M.

Theranostics. 2013 Nov 2;3(11):903-13. doi: 10.7150/thno.5938. eCollection 2013.

35.

Anaphylaxis caused by mosquito allergy in systemic mastocytosis.

Reiter N, Reiter M, Altrichter S, Becker S, Kristensen T, Broesby-Olsen S, Church MK, Metz M, Maurer M, Siebenhaar F.

Lancet. 2013 Oct 19;382(9901):1380. doi: 10.1016/S0140-6736(13)61605-0. No abstract available.

PMID:
24139121
36.

Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial.

Siebenhaar F, Förtsch A, Krause K, Weller K, Metz M, Magerl M, Martus P, Church MK, Maurer M.

Allergy. 2013 Jul;68(7):949-52. doi: 10.1111/all.12159. Epub 2013 Jun 4.

PMID:
23734572
37.

Practical algorithm for diagnosing patients with recurrent wheals or angioedema.

Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K.

Allergy. 2013 Jun;68(6):816-9. doi: 10.1111/all.12153. Epub 2013 May 6.

PMID:
23646863
38.

Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4.

Hendrix S, Kramer P, Pehl D, Warnke K, Boato F, Nelissen S, Lemmens E, Pejler G, Metz M, Siebenhaar F, Maurer M.

FASEB J. 2013 Mar;27(3):920-9. doi: 10.1096/fj.12-204800. Epub 2012 Nov 27.

PMID:
23193170
39.

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, Gleixner KV, Grattan C, Hadzijusufovic E, Hägglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude-Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Várkonyi J, Yavuz S, Hartmann K.

Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20. Review.

PMID:
23179435
40.

Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.

Magerl M, Rother M, Bieber T, Biedermann T, Brasch J, Dominicus R, Hunzelmann N, Jakob T, Mahler V, Popp G, Schäkel K, Schlingensiepen R, Schmitt J, Siebenhaar F, Simon JC, Staubach P, Wedi B, Weidner C, Maurer M.

J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e363-9. doi: 10.1111/j.1468-3083.2012.04689.x. Epub 2012 Aug 29.

PMID:
22928719
41.

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.

Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, Zuberbier T, Maurer M.

Allergy. 2012 Jul;67(7):943-50. doi: 10.1111/j.1398-9995.2012.02843.x. Epub 2012 May 15.

PMID:
22583335
42.

Miltefosine: a novel treatment option for mast cell-mediated diseases.

Maurer M, Magerl M, Metz M, Weller K, Siebenhaar F.

J Dermatolog Treat. 2013 Aug;24(4):244-9. doi: 10.3109/09546634.2012.671909. Epub 2012 Aug 5. Review.

PMID:
22385017
43.

[Childhood-onset mastocytosis].

Siebenhaar F, Weller K, Blume-Peytavi U, Maurer M.

Hautarzt. 2012 Feb;63(2):104-9. doi: 10.1007/s00105-011-2201-2. Review. German.

PMID:
22290278
44.

Management of chronic spontaneous urticaria in real life--in accordance with the guidelines? A cross-sectional physician-based survey study.

Weller K, Viehmann K, Bräutigam M, Krause K, Siebenhaar F, Zuberbier T, Maurer M.

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):43-50. doi: 10.1111/j.1468-3083.2011.04370.x. Epub 2011 Dec 8.

PMID:
22150693
45.

Cost-intensive, time-consuming, problematical? How physicians in private practice experience the care of urticaria patients.

Weller K, Viehmann K, Bräutigam M, Krause K, Siebenhaar F, Zuberbier T, Maurer M.

J Dtsch Dermatol Ges. 2012 May;10(5):341-7. doi: 10.1111/j.1610-0387.2011.07822.x. Epub 2011 Nov 23.

PMID:
22111985
46.

Chronic spontaneous urticaria: how to assess quality of life in patients receiving treatment.

Weller K, Church MK, Kalogeromitros D, Krause K, Magerl M, Metz M, Pisarevskaja D, Siebenhaar F, Maurer M.

Arch Dermatol. 2011 Oct;147(10):1221-3. doi: 10.1001/archdermatol.2011.310. No abstract available.

PMID:
22006145
47.

H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects--a retrospective survey study.

Weller K, Ziege C, Staubach P, Brockow K, Siebenhaar F, Krause K, Altrichter S, Church MK, Maurer M.

PLoS One. 2011;6(9):e23931. doi: 10.1371/journal.pone.0023931. Epub 2011 Sep 1.

48.

High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria.

Staubach P, Dechene M, Metz M, Magerl M, Siebenhaar F, Weller K, Zezula P, Eckhardt-Henn A, Maurer M.

Acta Derm Venereol. 2011 Sep;91(5):557-61. doi: 10.2340/00015555-1109.

49.

Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria.

Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, Siebenhaar F, Weller K, Zuberbier T, Maurer M.

Int Arch Allergy Immunol. 2011;154(2):177-80. doi: 10.1159/000320233. Epub 2010 Aug 24.

PMID:
20733327
50.

[Therapeutic alternatives for antihistamine-refractory urticaria].

Maurer M, Altrichter S, Ardelean E, Krause K, Magerl M, Metz M, Siebenhaar F, Weller K, Zuberbier T.

Hautarzt. 2010 Sep;61(9):765-9. doi: 10.1007/s00105-010-1934-7. German.

PMID:
20711555

Supplemental Content

Loading ...
Support Center